Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 216

Sort by

Sort Order Select

Journal Articles

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

Daria Frank, Pradeep Kumar Patnana, Jan Vorwerk, Lianghao Mao, Lavanya Mokada Gopal, Noelle Jung, Thorben Hennig, Leo Ruhnke, Joris Maximillian Frenz, Maithreyan Kuppusamy, Robert Autry, Lanying Wei, Kaiyan Sun, Helal Mohammed Mohammed Ahmed, Axel Künstner, Hauke Busch, Heiko Müller, Stephan Hutter, Gregor Hoermann, Longlong Liu, Xiaoqing Xie, Yahya Al-Matary, Subbaiah Chary Nimmagadda, Fiorella Charles Cano, Michael Heuser, Felicitas Thol, Gudrun Göhring, Doris Steinemann, Jürgen Thomale, Theo Leitner, Anja Fischer, Roland Rad, Christoph Röllig, Heidi Altmann, Desiree Kunadt, Wolfgang E. Berdel, Jana Hüve, Felix Neumann, Jürgen Klingauf, Virginie Calderon, Bertram Opalka, Ulrich Dührsen, Frank Rosenbauer, Martin Dugas, Julian Varghese, Hans Christian Reinhardt, Nikolas von Bubnoff, Tarik Möröy, Georg Lenz, Aarif M. N. Batcha, Marianna Giorgi, Murugan Selvam, Eunice Wang, Shannon K. McWeeney, Jeffrey W. Tyner, Friedrich Stölzel, Matthias Mann, Ashok Kumar Jayavelu, Cyrus Khandanpour

Blood (2023) 142 (25): 2175–2191.

https://doi.org/10.1182/blood.2022015752

Published: 2023

Includes: Supplemental data

Journal Articles

D DX41 -Low Expression Mimics Germline DDX41 -Phenotype in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 820.

https://doi.org/10.1182/blood-2023-187419

Published: 2023

Journal Articles

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Blood (2023) 142 (Supplement 1): 721.

https://doi.org/10.1182/blood-2023-186160

Published: 2023

Journal Articles

Risk Stratification of Patients with RUNX1- mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2023-174059

Published: 2023

Journal Articles

German AMLCG-Survivorship Study: Anxiety and Depression Symptoms in AML Long-Term Survivors

Dennis Görlich, Eva Telzerow, Maria Cristina Sauerland, Anna Sophia Moret, Maja Rothenberg-Thurley, Friederike H.A. Mumm, Susanne Amler, Wolfgang E. Berdel, Bernhard J. Wörmann, Utz Krug, Jan Braess, Pia Heußner, Wolfgang Hiddemann, Karsten Spiekermann, Klaus H. Metzeler

Blood (2022) 140 (Supplement 1): 942–943.

https://doi.org/10.1182/blood-2022-156647

Published: 2022

Journal Articles

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

Blood (2022) 140 (Supplement 1): 936–939.

https://doi.org/10.1182/blood-2022-165395

Published: 2022

Journal Articles

Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia

Christian Rausch, Maja Rothenberg-Thurley, Annika Maria Dufour, Stephanie Schneider, Hanna Gittinger, Maria Cristina Sauerland, Dennis Görlich, Utz Krug, Wolfgang E. Berdel, Bernhard Josef Woermann, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann, Tobias Herold, Klaus H. Metzeler

Blood (2022) 140 (Supplement 1): 3408–3409.

https://doi.org/10.1182/blood-2022-167022

Published: 2022

Journal Articles

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Blood (2022) 140 (Supplement 1): 523–525.

https://doi.org/10.1182/blood-2022-157126

Published: 2022

Journal Articles

Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

Blood (2022) 140 (Supplement 1): 6262–6264.

https://doi.org/10.1182/blood-2022-164702

Published: 2022

Journal Articles

Secondary Neoplasms in AML Long-Term Survivors: Even More Cancer to Come?

Anna Sophia Moret, Eva Telzerow, Maria Cristina Sauerland, Simon M. Krauss, Maja Rothenberg-Thurley, Friederike H.A. Mumm, Jan Braess, Bernhard J. Wörmann, Utz Krug, Wolfgang E. Berdel, Wolfgang Hiddemann, Karsten Spiekermann, Pia Heußner, Dennis Görlich, Klaus H. Metzeler

Blood (2022) 140 (Supplement 1): 690–691.

https://doi.org/10.1182/blood-2022-163530

Published: 2022

Journal Articles

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Blood (2022) 140 (Supplement 1): 510–512.

https://doi.org/10.1182/blood-2022-162235

Published: 2022

Journal Articles

Life Satisfaction and Quality of Life in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study

Eva Telzerow, Dennis Görlich, Maria Cristina Sauerland, Anna Sophia Moret, Maja Rothenberg-Thurley, Simon M. Krauss, Friederike H.A. Mumm, Susanne Amler, Wolfgang E. Berdel, Bernhard J. Wörmann, Utz Krug, Jan Braess, Pia Heußner, Wolfgang Hiddemann, Karsten Spiekermann, Klaus H. Metzeler

Blood (2022) 140 (Supplement 1): 5293–5295.

https://doi.org/10.1182/blood-2022-165429

Published: 2022

Journal Articles

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Blood (2022) 140 (Supplement 1): 2126–2129.

https://doi.org/10.1182/blood-2022-157684

Published: 2022

Journal Articles

CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Blood (2022) 139 (1): 87–103.

https://doi.org/10.1182/blood.2020009680

Published: 2022

Includes: Supplemental data

Journal Articles

High Prevalence of CHF and Diabetes in AML Long-Term Survivors - a Patient Forever?

Anna Sophia Moret, Eva Telzerow, Maja Rothenberg-Thurley, Maria Cristina Sauerland, Elke Burgard, Friederike H. A. Mumm, Jan Braess, Bernhard J. Wörmann, Utz Krug, Wolfgang E. Berdel, Wolfgang Hiddemann, Karsten Spiekermann, Pia Heußner, Klaus Kraywinkel, Dennis Görlich, Klaus H. Metzeler

Blood (2021) 138 (Supplement 1): 4127.

https://doi.org/10.1182/blood-2021-149149

Published: 2021

Journal Articles

Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes

Blood (2021) 138 (Supplement 1): 685.

https://doi.org/10.1182/blood-2021-153015

Published: 2021

Journal Articles

A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse

Blood (2021) 138 (Supplement 1): 2345.

https://doi.org/10.1182/blood-2021-145859

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Blood (2021) 138 (Supplement 1): 173.

https://doi.org/10.1182/blood-2021-145167

Published: 2021

Journal Articles

Characteristics and Outcome of Elderly Patients (> 55 Years) with Acute Lymphoblastic Leukemia (ALL)

Daniela V. Wenge, Klaus Wethmar, Corinna Klar, Hedwig Kolve, Tim Sauer, Linus Angenendt, Georg Evers, Simon Call, Andrea Kerkhoff, Cyrus Khandanpour, Torsten Kessler, Rolf M. Mesters, Christoph Schliemann, Jan-Henrik Mikesch, Christian Reicherts, Monika Brüggemann, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes

Blood (2021) 138 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2021-146459

Published: 2021

Journal Articles

Quality of Life and Life Satisfaction in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study

Eva Telzerow, Dennis Görlich, Maja Rothenberg-Thurley, Maria Cristina Sauerland, Anna Sophia Moret, Friederike H. A. Mumm, Susanne Amler, Wolfgang E. Berdel, Bernhard J. Wörmann, Utz Krug, Jan Braess, Pia Heußner, Wolfgang Hiddemann, Karsten Spiekermann, Klaus H. Metzeler

Blood (2021) 138 (Supplement 1): 2289.

https://doi.org/10.1182/blood-2021-147027

Published: 2021

NARROW

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

D DX41 -Low Expression Mimics Germline DDX41 -Phenotype in Acute Myeloid Leukemia

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Risk Stratification of Patients with RUNX1- mutated Acute Myeloid Leukemia

German AMLCG-Survivorship Study: Anxiety and Depression Symptoms in AML Long-Term Survivors

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

Secondary Neoplasms in AML Long-Term Survivors: Even More Cancer to Come?

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Life Satisfaction and Quality of Life in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

High Prevalence of CHF and Diabetes in AML Long-Term Survivors - a Patient Forever?

Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes

A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse

Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Characteristics and Outcome of Elderly Patients (> 55 Years) with Acute Lymphoblastic Leukemia (ALL)

Quality of Life and Life Satisfaction in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only